DaVita (NYSE:DVA) Stock Price Crosses Above Two Hundred Day Moving Average Following Analyst Downgrade

DaVita Inc. (NYSE:DVA)’s stock price crossed above its 200-day moving average during trading on Monday after Wall Street Zen upgraded the stock from a hold rating to a buy rating. The stock has a 200-day moving average of $128.91 and traded as high as $150.22. DaVita shares last traded at $150.0610, with a volume of 640,484 shares trading hands.

Several other equities research analysts also recently issued reports on DVA. Truist Financial set a $158.00 price objective on DaVita in a report on Thursday, February 5th. UBS Group boosted their price target on DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Barclays boosted their price target on DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a report on Tuesday, February 3rd. Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. Finally, TD Cowen reiterated a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $155.80.

Institutional Investors Weigh In On DaVita

Institutional investors have recently made changes to their positions in the company. Elevation Wealth Partners LLC grew its stake in DaVita by 147.3% during the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after buying an additional 165 shares during the last quarter. Caitlin John LLC bought a new position in DaVita during the 4th quarter worth $34,000. Canada Pension Plan Investment Board bought a new position in DaVita during the 2nd quarter worth $43,000. Sankala Group LLC bought a new position in DaVita during the 4th quarter worth $39,000. Finally, iSAM Funds UK Ltd bought a new position in DaVita during the 3rd quarter worth $46,000. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Performance

The stock has a market capitalization of $9.92 billion, a P/E ratio of 14.99, a P/E/G ratio of 0.51 and a beta of 0.92. The stock has a 50 day moving average of $147.22 and a 200 day moving average of $129.19.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. The firm had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The firm’s revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the business earned $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.